Início › Câncer de Ovário › Louisiana › New Orleans
Ensaios clínicos de Câncer de Ovário em New Orleans, LA
12 estudos para Câncer de Ovário estão buscando participantes em locais em New Orleans e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RecrutandoFase 3
- Louisiana State University HSC - NO Cancer Center, New Orleans
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RecrutandoFase 2/3
- University Medical Center New Orleans, New Orleans
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecrutandoFase 2
- Ochsner Medical Center Jefferson, New Orleans
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RecrutandoEstudo observacional
- Ochsner Clinic Foundation, New Orleans
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RecrutandoFase 2
- University Medical Center New Orleans /ID# 274755, New Orleans
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecrutandoFase 3
- Ochsner Clinic Foundation, New Orleans
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecrutandoEstudo observacional
- Tulane Cancer Center, New Orleans
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Recrutando
- Louisiana State University Health Science Center, New Orleans
- University Medical Center New Orleans, New Orleans
- West Jefferson Medical Center, Marrero · a 4 mi de distância
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecrutandoFase 3
- University Medical Center New Orleans, New Orleans
- Ochsner Baptist Medical Center, New Orleans
- Ochsner Medical Center Jefferson, New Orleans
- e mais 1
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecrutandoFase 1/2
- Louisiana State University Health Sciences Center, New Orleans
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
RecrutandoFase 3
- LSU Health New Orleans, New Orleans
- University Medical Center New Orleans, New Orleans
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, New Orleans
Ensaios de Câncer de Ovário em outras cidades
- Houston, TX89 estudos
- New York City, NY69 estudos
- Boston, MA61 estudos
- Los Angeles, CA50 estudos
- Nashville, TN49 estudos
- Arlington, VA46 estudos
- Philadelphia, PA44 estudos
- Columbus, OH39 estudos
- St. Louis, MO38 estudos
- Chicago, IL36 estudos
- San Antonio, TX31 estudos
- Cleveland, OH30 estudos
Outros estudos em New Orleans
- Câncer (todos os tipos)12 estudos
- Câncer de Mama11 estudos
- Câncer de Próstata10 estudos
- Câncer Endometrial9 estudos
- Câncer Metastático9 estudos
- Câncer de Pulmão9 estudos
- Câncer de Pulmão de Não Pequenas Células9 estudos
- Doença Cardiovascular9 estudos
- Obesidade8 estudos
- Doença Hepática Esteatótica8 estudos
- Câncer Colorretal8 estudos
- Fibrilação Atrial8 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.